BioCentury | Jan 4, 2021
Deals

Angelini adds registrational epilepsy program via $610M Arvelle takeout

...with more than $100 million in financing and in-licensed exclusive European rights to anti-epileptic cenobamate from SK Biopharmaceuticals...
BioCentury | Aug 14, 2020
Deals

EU closing in on COVID-19 vaccine deals with J&J, GSK-Sanofi as COVAX works toward equitable access

...see “Pfizer Lays out Two Phases of COVID-19 Vaccine Pricing”). Elizabeth S. Eaton Johnson & Johnson GlaxoSmithKline plc Sanofi Novavax Inc. SK Biopharmaceuticals Co. Ltd. World...
BioCentury | Jul 3, 2020
Finance

On heels of $100M raise, Annexon joins burgeoning IPO queue

...newly public or soon-to-be public companies. Headlining the week were a pair of Asian biopharmas: SK Biopharmaceuticals Co. Ltd....
BioCentury | Jul 2, 2020
Finance

SK becomes Korea’s third-largest public healthcare company after $800M IPO

...Ceiling in First Day on Shanghai” ; “Akouos Outshines Peers Among NASDAQ IPO Trio” ). SK Biopharmaceuticals Co. Ltd....
...cell therapy company SCM Lifescience (KOSDAQ:298060) raised $154.3 million on June 17. Elizabeth S. Eaton, Staff Writer SK Biopharmaceuticals Co. Ltd. Gencurix...
BioCentury | Jun 3, 2020
Finance

Daily Chart: IPO queue grows to 20 life sciences companies

...Inc. Forma Therapeutics Inc. Repare Therapeutics Inc. Generation Bio Co. Avidity Biosciences LLC Vaxcyte Inc. Royalty Pharma Burning Rock Biotech Arya Sciences Acquisition Corp. SK Biopharmaceuticals Co. Ltd. SCM...
BioCentury | Nov 23, 2019
Company News

Nov. 22 Company Quick Takes: AZ’s Btk inhibitor gains expanded approval; plus WuXi Vaccines, SK Bio, ViiV, Horizon and Neon

...with commercial vaccine product. FDA approves anti-epileptic from Korea-based SK FDA approved Xcopri cenobamate from SK Biopharmaceuticals Co. Ltd....
...Generic) NEO-PTC-01 teprotumumab (HZN-001, RV001, r1507, rg1507) Cenobamate (YKP3089) AstraZeneca plc ViiV Healthcare Ltd. NIH National Institutes of Health Neon Therapeutics Inc. Horizon Pharma plc SK Biopharmaceuticals Co. Ltd. WuXi...
BioCentury | Apr 18, 2019
Company News

Three steps forward, one step back for AI drug discovery

...technology to identify non-small cell lung cancer (NSCLC) therapeutics with new mechanisms of action for SK Biopharmaceuticals Co. Ltd....
...combing through the literature, genomics data and companies’ in-house databases. Mark Zipkin, Staff Writer Atomwise Inc. IBM Corp. IBM Watson SK Biopharmaceuticals Co. Ltd. twoXAR...
BioCentury | Apr 6, 2019
Finance

Everybody up

...linaclotide to treat irritable bowel syndrome with constipation (IBS-C) Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Licensed from SK Biopharmaceuticals Co. Ltd....
BioCentury | Feb 16, 2019
Company News

Emerging company roundup: Passage, IFM, Grey Wolf, Culture

...Partners and H.I.G. BioHealth Partners and in-licensed exclusive European rights to a late-stage anti-epileptic from SK Biopharmaceuticals Co. Ltd....
BioCentury | Feb 15, 2019
Company News

Axovant spins out small molecule team to form CNS-focused newco

...raised more than $100 million and in-licensed exclusive European rights to a late-stage anti-epileptic from SK Biopharmaceuticals Co. Ltd....
...NASDAQ:AXON) Arvelle Therapeutics GmbH, Basel, Switzerland SK Biopharmaceuticals Co. Ltd., Seoul, South Korea Business: Neurology Mark Zipkin Cenobamate (YKP3089) Axovant Sciences Ltd. SK Biopharmaceuticals Co. Ltd....
Items per page:
1 - 10 of 48
BioCentury | Jan 4, 2021
Deals

Angelini adds registrational epilepsy program via $610M Arvelle takeout

...with more than $100 million in financing and in-licensed exclusive European rights to anti-epileptic cenobamate from SK Biopharmaceuticals...
BioCentury | Aug 14, 2020
Deals

EU closing in on COVID-19 vaccine deals with J&J, GSK-Sanofi as COVAX works toward equitable access

...see “Pfizer Lays out Two Phases of COVID-19 Vaccine Pricing”). Elizabeth S. Eaton Johnson & Johnson GlaxoSmithKline plc Sanofi Novavax Inc. SK Biopharmaceuticals Co. Ltd. World...
BioCentury | Jul 3, 2020
Finance

On heels of $100M raise, Annexon joins burgeoning IPO queue

...newly public or soon-to-be public companies. Headlining the week were a pair of Asian biopharmas: SK Biopharmaceuticals Co. Ltd....
BioCentury | Jul 2, 2020
Finance

SK becomes Korea’s third-largest public healthcare company after $800M IPO

...Ceiling in First Day on Shanghai” ; “Akouos Outshines Peers Among NASDAQ IPO Trio” ). SK Biopharmaceuticals Co. Ltd....
...cell therapy company SCM Lifescience (KOSDAQ:298060) raised $154.3 million on June 17. Elizabeth S. Eaton, Staff Writer SK Biopharmaceuticals Co. Ltd. Gencurix...
BioCentury | Jun 3, 2020
Finance

Daily Chart: IPO queue grows to 20 life sciences companies

...Inc. Forma Therapeutics Inc. Repare Therapeutics Inc. Generation Bio Co. Avidity Biosciences LLC Vaxcyte Inc. Royalty Pharma Burning Rock Biotech Arya Sciences Acquisition Corp. SK Biopharmaceuticals Co. Ltd. SCM...
BioCentury | Nov 23, 2019
Company News

Nov. 22 Company Quick Takes: AZ’s Btk inhibitor gains expanded approval; plus WuXi Vaccines, SK Bio, ViiV, Horizon and Neon

...with commercial vaccine product. FDA approves anti-epileptic from Korea-based SK FDA approved Xcopri cenobamate from SK Biopharmaceuticals Co. Ltd....
...Generic) NEO-PTC-01 teprotumumab (HZN-001, RV001, r1507, rg1507) Cenobamate (YKP3089) AstraZeneca plc ViiV Healthcare Ltd. NIH National Institutes of Health Neon Therapeutics Inc. Horizon Pharma plc SK Biopharmaceuticals Co. Ltd. WuXi...
BioCentury | Apr 18, 2019
Company News

Three steps forward, one step back for AI drug discovery

...technology to identify non-small cell lung cancer (NSCLC) therapeutics with new mechanisms of action for SK Biopharmaceuticals Co. Ltd....
...combing through the literature, genomics data and companies’ in-house databases. Mark Zipkin, Staff Writer Atomwise Inc. IBM Corp. IBM Watson SK Biopharmaceuticals Co. Ltd. twoXAR...
BioCentury | Apr 6, 2019
Finance

Everybody up

...linaclotide to treat irritable bowel syndrome with constipation (IBS-C) Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Licensed from SK Biopharmaceuticals Co. Ltd....
BioCentury | Feb 16, 2019
Company News

Emerging company roundup: Passage, IFM, Grey Wolf, Culture

...Partners and H.I.G. BioHealth Partners and in-licensed exclusive European rights to a late-stage anti-epileptic from SK Biopharmaceuticals Co. Ltd....
BioCentury | Feb 15, 2019
Company News

Axovant spins out small molecule team to form CNS-focused newco

...raised more than $100 million and in-licensed exclusive European rights to a late-stage anti-epileptic from SK Biopharmaceuticals Co. Ltd....
...NASDAQ:AXON) Arvelle Therapeutics GmbH, Basel, Switzerland SK Biopharmaceuticals Co. Ltd., Seoul, South Korea Business: Neurology Mark Zipkin Cenobamate (YKP3089) Axovant Sciences Ltd. SK Biopharmaceuticals Co. Ltd....
Items per page:
1 - 10 of 48